1 / 5

10% discount on Rising Stars Outlook - Valid upto 7th june 2016

Bharat Book Bureau provides the report; on “Rising Stars New Emergence Of Potential TX & DX Options Could Transform The Current Landscape For Liver Diseases (Nash)” This report is a worldwide need for new therapies to treat the global epidemic of NASH, this report help in that. https://www.bharatbook.com/healthcare-market-research-reports-416131/rising-stars-new-emergence-potential-tx-dx-transform-diseases.html

bharatbookseo
Download Presentation

10% discount on Rising Stars Outlook - Valid upto 7th june 2016

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 10% discount on Rising Stars Outlook - Valid upto 7th june 2016

  2. Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!  W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  3. Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year. W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  4. Table of Contents Conatus Pharmaceuticals (CNAT) Trends In Overall Population Driven By Significant Improvement In MELD Galectin Therapeutics (GALT) Reversing Late-stage NASH (Advanced Fibrosis) Key Milestones (Galt) Key Milestones (Glmd) Galmed Pharmaceuticals Aramchol: Phase Iia Data – Relative Change In Liver-fat Concentration Aramchol: Differentiated Mode Of Action Aramchol: Clinical Trials And Its Endpoints W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

  5. To view the full Executive Summary and Table of Contents, please visit: 10% discount on Rising Stars Outlook - Valid upto 7th june 2016 Contact Us:-Call India: +91-22-27810772/73Email id : poonam@bharatbook.comWebsite : www.bharatbook.comOur Blog : https://www.bharatbook.com/blog/ W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  poonam@bharatbook.com

More Related